Glycated hemoglobin News and Research

RSS

Alogliptin adds benefits to diabetes monotherapy

Alogliptin is an effective add-on to glimepiride therapy for improving glycemic control in Japanese patients with Type 2 diabetes, show study findings.

18 Jul 2012

NICE: GPs must target diabetes prevention

Guidance for the prevention of type 2 diabetes out today from NICE urges GPs to step up efforts to get high-risk patients onto lifestyle intervention programmes. As trailed at the end of last year, the guidance recommends that GPs run checks on their practice register using a validated computerised diabetes risk tool and invite those falling into high-risk groups for a proper risk assessment, in line with the NHS Health Check programme.

12 Jul 2012

Two-drug combo increases diabetes patients’ goal achievement

Post-hoc analysis of randomized trial results shows that treating individuals with Type 2 diabetes with a combination of phentermine and topiramate increases their achievement of goals recommended for the management of their condition.

10 Jul 2012

Abbott announces CE Marking for ARCHITECT HbA1c assay

More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformite Europeenne) for the Abbott ARCHITECT HbA1c (IA) Assay.

10 Jul 2012

Diabetes on the rise among Chinese teenagers

A study led by researchers at the University of North Carolina at Chapel Hill found Chinese teenagers have a rate of diabetes nearly four times greater than their counterparts in the United States. The rise in the incidence of diabetes parallels increases in cardiovascular risk, researchers say, and is the result of a Chinese population that is growing increasingly overweight.

6 Jul 2012

Folic acid ‘may benefit diabetics’

Folic acid supplementation can significantly reduce homocysteine levels and may therefore offer an approach for lowering cardiovascular risk among patients with Type 2 diabetes, report researchers.

2 Jul 2012

Recurring diabetic foot ulcers ‘predictable’

The risk for recurring diabetic foot ulcers is predicted by clinical characteristics, such as existing ulcer location, bone infection, and diabetes control, demonstrates research published in International Wound Journal.

29 Jun 2012

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics.

29 Jun 2012

Exercise-induced metabolic improvement not caused by just adipose change

The improvements in metabolic parameters that are achieved with increased physical activity are unlikely to be due to functional changes in adipose tissue alone, report researchers.

26 Jun 2012

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

25 Jun 2012

GI Dynamics announces clinical data about EndoBarrier Therapy at ASMBS meeting

GI Dynamics, Inc. announced today that clinical data about EndoBarrier Therapy, a breakthrough treatment for type 2 diabetes and/or obesity, was presented at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) in San Diego.

23 Jun 2012

Health care system or patient-directed programs help prevent or manage diabetes

A new study has found that programs aimed at helping people prevent or manage diabetes are most successful if they are directed at the patient or the health care system. Programs aimed at physicians were only successful for patients with poorer diabetes control.

23 Jun 2012

OSA underdiagnosed among primary care diabetes patients

Obstructive sleep apnea is commonly underdiagnosed in patients with Type 2 diabetes in primary care, suggest study findings.

22 Jun 2012

Omega 3 may not improve CV health

Daily omega 3 supplementation may not reduce risk for cardiovascular events in high-risk patients, show study findings.

20 Jun 2012

Exenatide ‑ a better alternative for add-on therapy?

Twice-daily exenatide may offer advantages over the standard glimepiride in patients with Type 2 diabetes inadequately controlled by metformin, suggest findings published in The Lancet.

19 Jun 2012

Insulin more effective add-on than sitagliptin in glucose control

Insulin seems to be a more effective add-on regimen than sitagliptin in patients with diabetes inadequately controlled by metformin monotherapy, show study findings.

15 Jun 2012

Study analyses impact of one-off advice session and ongoing support for patients with T2D

Research led by the University of Leicester concludes that people newly diagnosed with Type 2 diabetes need ongoing advice from GPs sustained over a number of years rather than a one-off session when they are first diagnosed.

14 Jun 2012

Almased helps patients with type 2 diabetes lose weight, gain better sugar control

A pilot study shows that a protein-rich meal replacement made from soy, yogurt, and honey (Almased) helps patients with type 2 diabetes lose weight, gain better control of their blood sugar, and decrease their daily insulin dose. Patients in the study also lowered their body mass index (BMI), waist and hip circumference, and fasting glucose levels, while improving their HDL-cholesterol and triglycerides.

12 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012